M2 Pharma - Therapy Areas - Inflammatory Disease

Celltrion Completes Enrolment for Global Phase II Clinical Trial with COVID-19 Treatment Candidate CT-P59

25 November 2020 - - Enrolment of 327 patients with mild-to-moderate symptoms of SARS-CoV-2 infection has completed in the global Phase II clinical trial of CT-P59, an anti-COVID-19 monoclonal antibod...

Vedanta Biosciences Names Karuna Therapeutics CFO Ignelzi to Its Board of Directors

25 November 2020 - - US-based clinical-stage company Vedanta Biosciences has appointed Troy Ignelzi as an independent member of its board of directors, the company said.

Ignelzi has more ...

FDA Grants Emergency Use Authorisation for Baricitinib in Hospitalised COVID-19

23 November 2020 - - Baricitinib, a drug it first identified as a potential treatment for COVID-19 by the company has been granted Emergency Use Authorization by the US Food and Drug Administration, U...

PureTech's LYT-100 Demonstrates Tolerability and Pharmacokinetic Proof-of-Concept in Phase 1 Multiple Ascending Dose and Food Effect Study

20 November 2020 - - US-based biotherapeutics company PureTech Health plc (LSE: PRTC) (NASDAQ: PRTC) has completed a Phase 1 multiple ascending dose and food effect study for LYT-100 (deupirfenidone),...

NeurodigitX unveils first digital inflammatory biomarker platform to support COVID-19 pandemic exit strategy

19 November 2020 - Digital health company, NeurodigitX reported on Wednesday the launch of Plastic Health platform, which allows a powerful mainstream bloodless assessment of inflammation levels in th...

Omeros Submits its Biologics License Application to US FDA for Narsoplimab in HSCT-TMA

18 November 2020 - - US-based Omeros Corp. (NASDAQ: OMER) has completed the rolling submission of its Biologics License Application to the US Food and Drug Administration for narsoplimab for the treat...